CellForge

Executive Summary

CellForge is a privately-held biotechnology company developing next-generation, off-the-shelf cell therapies for oncology and autoimmune diseases. Leveraging its proprietary platform, the company engineers immune cells (e.g., CAR-T, CAR-NK) with enhanced persistence, targeting, and resistance to the immunosuppressive tumor microenvironment. Founded in 2021 and headquartered in Seattle, CellForge has raised approximately $250 million in funding, reflecting strong investor confidence in its allogeneic approach that aims to overcome key limitations of autologous therapies, including manufacturing delays, high cost, and patient access. The company's lead program targets CD19-positive B-cell malignancies, currently in Phase 2 clinical development, with additional preclinical programs in autoimmune indications such as lupus and type 1 diabetes. CellForge's differentiated platform includes novel synthetic signaling domains and stealth technologies to reduce immune rejection, potentially enabling repeat dosing and broader patient applicability. With a robust pipeline and a seasoned management team, CellForge is positioned to address significant unmet needs in cancer and autoimmune diseases, though clinical validation and manufacturing scalability remain key risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 interim data readout for lead CAR-T therapy in relapsed/refractory B-cell malignancies65% success
• Q1 2027FDA clearance of IND for autoimmune disease program (lupus)80% success
• Q2 2027Strategic partnership or licensing deal for off-the-shelf platform in Asia or Europe50% success